|
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical research trials and A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus clinical trial. Participants frequently obtain the most expert healthcare available for their A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus  A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
For Condition: Diabetes
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The objectives of the study are: To determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 35 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 35 to 75 - Type 2 diabetes for longer than 3 months - HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening - FPG (fasting plasma glucose) greater than 126 mg/dL at screening - BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: - Type I diabetes - Type 2 diabetes patients currently treated with insulin - Type 2 diabetes patients curently or previously treated with Actos, Avandia or Rezulin - FPG (fasting plasma glucose) greater than 270 mg/dL at baseline - Impaired liver or kidney function - Triglycerides greater than 600 mg/dL - Uncontrolled hypertension - Pregnant or lactating women - Women not using adequate contraception
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: WM16177;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057317
Other DiabetesStudies:
1. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
2. Developing and Implementing a Quality Measure for Glycemic Control
3. Clinical Trial of Footwear in Patients with Diabetes
4. Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans
5. Research Study in Patients with Persistent Macular Edema
Related Studies:
Other Diabetes Clinical Trials
Other Oregon Clinical Trials
Other Tualatin Clinical Trials
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
